New Biomarkers and AI Aim to Cut Unnecessary Prostate Biopsies Before the Needle

Prostate cancer remains one of the most common malignancies and a leading cause of cancer-related death among men worldwide, yet the tests used to decide who needs a biopsy are surprisingly blunt. A new review published in Medical Oncology by researchers at Shanghai Jiao Tong University School of Medicine maps the fast-moving field of pre-biopsy diagnostics, arguing that a paradigm shift is underway: away from single-parameter screening and toward multimodal integration that combines molecular biomarkers, advanced imaging, and artificial intelligence. The goal is deceptively simple to state and fiendishly hard to achieve—telling cancer apart from benign prostatic disease before a single needle enters the gland.

The core problem lies in what clinicians call the diagnostic gray zone. Serum prostate-specific antigen (PSA), the workhorse of prostate cancer screening since the early 1990s, loses much of its discriminative power when values fall between 4 and 10 ng/mL, a range where benign prostatic hyperplasia and prostatitis routinely elevate the marker just as aggressively as tumors do. Multiparametric MRI, the other pillar of modern triage, has its own blind spot: lesions graded PI-RADS category 3, the equivocal middle of the Prostate Imaging Reporting and Data System, carry genuinely ambiguous cancer probability. In this gray zone, the overlap between malignant and benign disease drives a substantial number of unnecessary biopsies—procedures that carry real morbidity, from bleeding and infection to the psychological burden of waiting, and that frequently detect indolent cancers a patient might never have needed to know about.

The review’s authors, led by Zijie Nie and corresponding author Lingling Wu, organize the emerging solutions into three broad categories: liquid-based molecular biomarkers, advanced imaging modalities, and integrative frameworks that fuse multiple data streams. On the biomarker front, the most mature tools refine what PSA already tells us. The Prostate Health Index (PHI), a mathematical combination of total PSA, free PSA, and the precursor form p2PSA, has been validated across European and Asian populations, with recent large Chinese cohort data confirming its utility and newer derivatives such as PHI density—PHI divided by prostate volume—outperforming PSA density in equivocal MRI settings. The 4Kscore, a four-kallikrein blood panel, has shown its worth as a reflex test after elevated PSA; in the GÖTEBORG-2 screening trial it performed well as a second-line discriminator, and the ProScreen randomized trial demonstrated that combining PSA, the kallikrein panel, and MRI can streamline screening pathways.

Perhaps the most conceptually elegant of the refined PSA tools is IsoPSA, which abandons concentration measurement altogether. Instead of asking how much PSA is in the blood, IsoPSA interrogates the structural heterogeneity of the PSA protein itself—cancerous tissue produces subtly different molecular forms of the enzyme than benign tissue does. Prospective multicenter validation showed improved detection of both any cancer and high-grade disease compared with conventional total PSA, and notably, its performance characteristics are unaffected by 5-alpha reductase inhibitors and alpha-blockers, drugs that confound standard PSA interpretation. A recent study further reported that IsoPSA density improves risk stratification and biopsy decision-making for clinically significant cancer.

Urine-based tests exploit a different biological logic: tumor-derived molecular signatures can be captured non-invasively from prostatic fluid expressed during a digital rectal examination or simply from first-catch urine. SelectMDx, a two-gene mRNA test, has been validated in prospective multicenter studies of biopsy-naïve men and compared directly against mpMRI in diagnostic meta-analyses. MyProstateScore (MPS), built around the TMPRSS2:ERG fusion gene and PCA3, has demonstrated a robust ability to rule out clinically significant cancer, including in men with equivocal PI-RADS 3 lesions—precisely the population where the clinical need is greatest. Its successor, MyProstateScore 2.0, an 18-gene urine test validated in JAMA Oncology, extends this approach to high-grade cancer detection using first-catch urine without any prior examination, removing a logistical barrier to widespread use.

Exosome technology represents a further step along the liquid biopsy frontier. The ExoDx Prostate IntelliScore test analyzes gene expression in urinary exosomes—nanoscale vesicles shed by prostate tissue—to predict high-grade cancer at initial biopsy in men with PSA between 2 and 10 ng/mL, with clinical performance confirmed across three independent prospective studies. Beyond RNA, researchers are mining exosomes for proteins and metabolites: proteomic profiling of urinary large extracellular vesicles, chemical affinity capture of plasma extracellular vesicles for large-scale biomarker discovery, and metabolomic fingerprints of vesicles from prostatic fluid all feature in the review as rapidly maturing avenues. Emerging candidates such as annexin A3, the homeobox protein engrailed-2 (EN2), CRISP3, and the cholinergic peptide SLURP1 add to a growing catalog of tumor-specific molecules detectable in urine.

MicroRNAs and metabolomics round out the molecular picture. Circulating and urinary microRNAs—including miR-21, miR-145, miR-30b-3p, and miR-375—have shown the ability to distinguish prostate cancer from benign lesions, with novel detection platforms such as silver nanoparticle sensors pushing toward point-of-care measurement. Metabolomics takes aim at the tumor’s altered biochemistry: sarcosine in urine, lipid species in exosomes, and serum metabolite panels have all discriminated cancer from benign prostatic hyperplasia within the PSA gray zone, and a recent systematic review of pre-diagnostic untargeted metabolomics supports their prospective value. The biological rationale is sound, since prostate cancer undergoes profound metabolic reprogramming, and metabolites often change earlier than structural imaging can detect.

On the imaging side, the review catalogues technologies that go beyond conventional mpMRI. Biparametric and abbreviated MRI protocols promise wider access with comparable detection accuracy. Magnetic resonance elastography measures the physical stiffness of tissue—cancers are typically harder than benign tissue—and tomoelastography based on multifrequency MRE has outperformed mpMRI in head-to-head comparisons. Amide proton transfer-weighted imaging, a chemical exchange saturation transfer technique, probes tissue pH and protein content at the molecular level and has added value to PI-RADS v2.1 in detecting clinically significant disease. Micro-ultrasound, with resolution roughly three times finer than standard ultrasound, performed comparably to MRI in biopsy-naïve men and was tested head-to-head against MRI-guided biopsy in the OPTIMUM randomized trial. Most striking is PSMA PET/CT, which images the prostate-specific membrane antigen expressed on tumor cells; studies such as PRIMARY have shown its additive value to mpMRI triage, and [18F]DCFPyL PET/CT has reduced unnecessary biopsies in PI-RADS 3/4 patients—though benign prostatic hyperplasia-related false positives remain its acknowledged Achilles’ heel.

The review’s central thesis, however, is that no single test will win. Instead, the field is converging on multimodal integration. Risk calculators such as Stockholm3—which combines protein biomarkers, genetic variants, and clinical variables—have been validated in multiethnic cohorts and combined productively with MRI. PSA density and PHI density refine biopsy thresholds when layered onto PI-RADS scores, and combining the PRIMARY score with PSA density helps avoid unnecessary biopsies after negative mpMRI. Artificial intelligence is the connective tissue of this shift: deep learning models detect clinically significant cancer on MRI with performance approaching that of expert radiologists, as demonstrated in the international PI-CAI study published in Lancet Oncology, while multimodal AI systems that fuse clinical data, biomarkers, and imaging inputs have improved detection beyond any single modality. Radiomics—high-throughput extraction of quantitative image features—adds another layer, with machine learning models predicting malignancy even in equivocal PI-RADS 3 lesions.

The implications for patients are concrete. By sharpening the boundary between cancer and its benign mimics before biopsy, these tools could spare thousands of men annually from invasive procedures that carry morbidity and psychological cost, while directing biopsies more precisely toward those with clinically significant disease. The authors emphasize that this is a paradigm shift from single-parameter screening to multimodal, AI-assisted decision-making—personalized risk stratification built from blood, urine, and image data. Challenges remain, including validation across diverse populations, cost, and clinical implementation, but the trajectory is clear: the diagnostic gray zone that has frustrated urologists for three decades is finally being mapped, molecule by molecule and pixel by pixel, and the biopsy needle may soon arrive only where it is truly needed.

Subject of Research: Non-invasive pre-biopsy diagnostic strategies for discriminating prostate cancer from benign prostatic diseases

Article Title: Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population

Article References: Nie, Z., Zhu, T., Chen, Y., Zhang, W., & Wu, L. (2026). Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population. Medical Oncology, 43(11), Article 305. https://doi.org/10.1007/s12032-026-03424-1

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03424-1

Keywords: prostate cancer, PSA, liquid biopsy, multiparametric MRI, biomarkers, PI-RADS, artificial intelligence, PSMA PET, urine tests, risk stratification, prostate biopsy, metabolomics